Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 7007-7009

  MacVane, Shawn H ^a   Crandon, Jared L ^a   Nichols, Wright W ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; CEFTAZIDIME; CYCLOPHOSPHAMIDE; DORIPENEM; ERTAPENEM; METALLO BETA LACTAMASE; NEW DELHI METALLO BETA LACTAMASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE; CARBAPENEM DERIVATIVE; METALLO-BETA-LACTAMASE (VIM-13), PSEUDOMONAS AERUGINOSA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENTEROBACTERIACEAE; ENZYME INHIBITION; ESCHERICHIA COLI; FEMALE; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; LEG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MURINAE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; THIGH; THIGH INFECTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CARBAPENEMS; CEFTAZIDIME; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 84908439740     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02662-14     Document Type: Article

References (16)

1. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20:440-458. http://dx.doi.org/10.1128/CMR.00001-07.
2. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
3. Johnson AP, Woodford N. 2013. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J. Med. Microbiol. 62:499-513. http://dx.doi.org/10.1099/jmm.0.052555-0.
4. Bush K. 2013. Carbapenemases: partners in crime. J. Glob. Antimicrob. Resist. 1:7-16. http://dx.doi.org/10.1016/j.jgar.2013.01.005.
5. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329. http://dx.doi.org/10.1093/jac/dkp197.
6. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob. Agents Chemother. 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
7. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
8. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2013. Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model. Antimicrob. Agents Chemother. 57:3936-3940. http://dx.doi.org/10.1128/AAC.00708-13.
9. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2014. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 58:1671-1677. http://dx.doi.org/10.1128/AAC.01946-13.
10. Girlich D, Poirel L, Carattoli A, Kempf I, Lartigue MF, Bertini A, Nordmann P. 2007. Extended-spectrum β-lactamase CTX-M-1 in Escherichia coli isolates from healthy poultry in France. Appl. Environ. Microbiol. 73:4681-4685. http://dx.doi.org/10.1128/AEM.02491-06.
11. Choi KH, Kumar A, Schweizer HP. 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64:391-397. http://dx.doi.org/10.1016/j.mimet.2005.06.001.
12. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 9th ed. Approved standard M07-A9. Clinical Laboratory Standards Institute, Wayne, PA.
13. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10.1128/AAC.00851-12.
14. Eagle H. 1950. Effect of schedule of administration on therapeutic efficacy of penicillin: importance of aggregate time penicillin remains at effectively bactericidal levels. Am. J. Med. 9:280-299. http://dx.doi.org/10.1016/0002-9343(50)90425-6.
15. Ehmann DE, Jahic H, Ross PL, Gu R-F, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J. Biol. Chem. 288:27960-27971. http://dx.doi.org/10.1074/jbc.M113.485979.
16. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob. Agents Chemother. 57:3299-3306. http://dx.doi.org/10.1128/AAC.01989-12.